ArticleESMO open2026

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

T Powles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.